Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1

Oncology Reports

Volumn 15, Issue 6, 2006, Pages 1417-1423

  Harada, Koji ^a   Kawashima, Yuichiro ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Oral squamous cell carcinoma; Predictive factor; S 1; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; MULTIENZYME COMPLEX; OROTATE PHOSPHORIBOSYLTRANSFERASE; OROTIDINE 5' PHOSPHATE DECARBOXYLASE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; URIDINE 5' PHOSPHATE SYNTHASE; URIDINE 5'-MONOPHOSPHATE SYNTHASE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; DRUG COMBINATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIENZYME COMPLEXES; OROTATE PHOSPHORIBOSYLTRANSFERASE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; OXONIC ACID; RNA, MESSENGER; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 39049175391     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.6.1417     Document Type: Article

References (27)

1. Johnson NW: Epidemiology of oral cancer in risk markers of oral disease. In: Oral Cancer. Vol. 2. Johnson NW (ed). Cambridge University Press, Cambridge, UK, pp3-26, 1991.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl 547: 25-29, 2002. (Pubitemid 34913460)
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284, 2003 (Pubitemid 36298898)
4. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor-selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
5. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn J Cancer Res 78: 748-755, 1987. (Pubitemid 17132408)
6. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition of oxonic acid on gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993. (Pubitemid 23267702)
7. Shirasaka T, Nakano K, Takechi T, et al: Antitumor effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. (Pubitemid 26171684)
8. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
9. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000. (Pubitemid 30411708)
10. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative Study Group (Lung Cancer Working Group), Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943, 2001. (Pubitemid 33015993)
11. Inuyama Y, Kida A, Tsukuda M, Kohno N and Satake B: Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390, 2001.
12. Chollet P, Schoffski P, Weigang-Kohler K, et al: EORTC Early Clinical Studies Group.Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264-1670, 2003.
13. Van den Brande J, Schoffski P, Schellens JH, et al: EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653, 2003. (Pubitemid 36411437)
14. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y and Sugita M: Chemotherapy Study Group of Head and Neck Cancer. Br J Cancer 93: 884-889, 2005.
15. Kawano K, Goto H, Kanda T and Yanagisawa S: Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 32: 633-637, 2003. (Pubitemid 37461506)
16. Kawasaki G, Yoshitomi I, Yanamoto S and Mizuno A: Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 717-723, 2002. (Pubitemid 41124708)
17. Johnston PJ, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
18. Pestalozzi BC, Peterson HF, Gelber RD, et al: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997. (Pubitemid 27209522)
19. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M and Sato I: Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 57: 50-54, 1999.
20. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin Cancer Res 4: 42371-42376, 1998.
21. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
22. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987. (Pubitemid 17064313)
23. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
24. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
25. Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88: 8977-8981, 1991. (Pubitemid 21915553)
26. Pullarkat ST, Stoelmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001. (Pubitemid 33757985)
27. Keyomarsi K, Samet J, Molnar G and Pardee AB: The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 268: 15142-15149, 1993. (Pubitemid 23206667)